Macrocyclic LRRK2 Inhibitors for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and other related disorders lack effective therapies targeting the LRRK2 kinase, which is implicated in these conditions, leading to inadequate management of symptoms and progression of the diseases.
Innovation Solution
Development of macrocycles and their pharmaceutically acceptable salts that exhibit potent and selective LRRK2 kinase inhibitory activity, providing a therapeutic approach to modulate LRRK2 activity and address the underlying pathophysiology of these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodegenerative diseases, then current standard of care is maintained, but effective therapy targeting LRRK2 kinase is not achieved
Solution Approach 1:
The patent modifies molecular parameters by incorporating macrocyclic ring structures and specific heterocyclic moieties (pyridine, pyrimidine, triazine) into the kinase inhibitor scaffold. These structural parameter changes enable potent and selective binding to LRRK2 kinase, achieving therapeutic effectiveness that conventional treatments cannot provide while maintaining specificity for the target disease pathway.
Solution Approach 2:
The invention creates composite molecular structures combining macrocyclic frameworks with various heterocyclic aromatic rings and substituent groups. This composite approach allows the molecule to simultaneously interact with multiple binding sites on LRRK2 kinase, enhancing both therapeutic effectiveness and selective targeting of the disease pathway.
2Reliability
If LRRK2 kinase inhibitors are developed, then disease-specific therapy is achieved, but selectivity and brain penetration must be optimized
Solution Approach 1:
The patent applies local quality by introducing specific heterocyclic moieties (pyridine at position 6, pyrimidine or triazine at position 2) with distinct chemical properties to different regions of the macrocyclic scaffold. These localized functional groups provide specific interactions with LRRK2 kinase residues, achieving high selectivity and potency while maintaining brain penetration through appropriate lipophilicity and molecular size.
3Reliability
If macrocyclic LRRK2 inhibitors are synthesized, then potent inhibition is achieved, but manufacturing complexity increases
Solution Approach 1:
The macrocyclic inhibitor molecules are designed as segmented structures comprising a core macrocyclic ring with detachable heterocyclic aromatic substituent groups. This segmentation allows independent optimization of the macrocycle scaffold and the heterocyclic moieties, facilitating modular synthesis approaches that reduce overall manufacturing complexity while maintaining high inhibitory potency through the combination of functional elements.
Data Source
AI summary
The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and (Ia); and pharmaceutically acceptable salts thereof, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.